Retrospective analysis reveals MRD improves outcomes in multiple myeloma, suggesting links to immune reconstitution.
Key Points
To analyze the evolution of minimal residual disease and normal plasma cells following autologous stem cell transplantation in multiple myeloma patients.
Retrospective analysis of 400 patients with newly diagnosed multiple myeloma (NDMM) undergoing ASCT.
Assessment of minimal residual disease (MRD) and normal plasma cells (NPCs) in bone marrow samples post-ASCT.
Evaluation of progression-free survival (PFS) and overall survival (OS) rates across MRD subgroups.
ASCT improved MRD status, particularly in low tumor burden patients.
Sustained MRD negativity correlated with longer PFS and better OS outcomes.
Normal plasma cell percentages were significantly lower in MRD-positive patients, affecting recovery trajectories.